Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes
Authors' conclusion
In ambulatory patients with T2DM, the presence and severity of MAFLD was strongly associated with an increased risk of supraventricular and ventricular arrhythmias on 24-hour Holter monitoring.
Study context
- Population
- Ambulatory patients with T2D who underwent 24-hour Holter monitoring (2015–2022) for clinical indications, without pre-existing permanent atrial fibrillation (AF), kidney failure or known liver diseases
- Participants
- 367 patients
- Exposure
- MAFLD vs no MAFLD
- MAFLDn = 238
- Without MAFLDn = 129reference
- Outcome
- Supraventricular and ventricular tachyarrhythmias on 24-hour Holter monitoring
Main finding
As reported in the abstract
Each group vs without MAFLDEstimate (95% CI)
MAFLD
aOR (PSVT) 2.04(1.04–4.00)
MAFLD
aOR (ventricular tachyarrhythmias) 2.44(1.16–5.11)
Observational data: associations, not effects.
Further findings
Prevalence of PSVT · significantly greater with MAFLD
Prevalence of paroxysmal AF · significantly greater with MAFLD
Prevalence of combined ventricular tachyarrhythmias · significantly greater with MAFLD
MAFLD with FIB-4 ≥ 1.3
- Risk of supraventricular and ventricular tachyarrhythmias even greater with MAFLD and FIB-4 ≥ 1.3
Original publication
Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes. Diabetes Metab. Published 28 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →